NCT03316573 2026-02-10Pembrolizumab in Neoplasms or LymphomasDana-Farber Cancer InstitutePhase 2 Suspended18 enrolled 16 charts
NCT02037529 2024-08-20Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast CancerAcademic and Community Cancer Research UnitedPhase 3 Suspended201 enrolled 19 charts